Abstract
Chronic stable angina pectoris is the most common manifestation of coronary artery disease and is associated with impaired quality of life and increased mortality. Signs and symptoms of angina result from an imbalance between myocardial oxygen supply and metabolic oxygen demands and they can be relieved by drugs that reduce metabolic oxygen demands and/or increase coronary blood flow to the ischemic area. Nowadays many patients continue to suffer from angina despite medical treatment and coronary bypass surgery and/or percutaneous interventions. Therefore, there is a medical need for developing new antianginal drug with different, but complementary, mechanisms of action that can be safely added to the current antianginal arsenal. This chapter briefly reviews the mechanism of action and the preliminary clinical efficacy and safety of some drugs under development for the treatment of chronic stable angina pectoris.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
